(Q45149602)

10 December 2017

Cationic microparticles are a potent delivery system for a HCV DNA vaccine (English)

1 reference

10 December 2017

13

Michael Houghton

1 reference

10 December 2017

8

Mark Wininger

1 reference

10 December 2017

3

Christine Dong

1 reference

10 December 2017

Derek T O'Hagan

1

1 reference

10 December 2017

Manmohan Singh

2

1 reference

10 December 2017

Mildred Ugozzoli

4

1 reference

10 December 2017

Kim Berger

5

1 reference

10 December 2017

Edward Glazer

6

1 reference

10 December 2017

Mark Selby

7

1 reference

10 December 2017

Philip Ng

9

1 reference

10 December 2017

Kevin Crawford

10

1 reference

10 December 2017

Xavier Paliard

11

1 reference

10 December 2017

Steven Coates

12

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

10 December 2017

1 reference

10 December 2017

23

1 reference

10 December 2017

5

1 reference

10 December 2017

672-680

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

10 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

The scientific challenge of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Hepatitis C virus infection in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Management of hepatitis C: a national survey of gastroenterologists and hepatologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Analysis of a successful immune response against hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Analysis of successful immune responses in persons infected with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Vaccination of chimpanzees against infection by the hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

DNA vaccines: immunology, application, and optimization*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Cationic microparticles: A potent delivery system for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.06.037

10.1016/J.VACCINE.2004.06.037

7 January 2021

Identifiers

DOI

1 reference

10 December 2017

1 reference